Pharmacology of cannabinoids in the treatment of epilepsy

Epilepsy and Behavior

Volumn 70, Issue , 2017, Pages 313-318

  Gaston, Tyler E ^a   Friedman, Daniel ^b  

^a The University of Alabama at Birmingham   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cannabidivarin; Cannabinoids; Pharmacology; Tetrahydrocannabinol; Tetrahydrocannabinolic acid; Tetrahydrocannabivarin

Indexed keywords

ANTICONVULSIVE AGENT; CANNABIDIOL; CANNABIDIVARIN; CANNABINOID; CHLORDIAZEPOXIDE; CLOBAZAM; CLONAZEPAM; DELTA9 TETRAHYDROCANNABIVARIN; DRONABINOL; ETHOSUXIMIDE; NORCLOBAZAM; TETRAHYDROCANNABINOLIC ACID; UNCLASSIFIED DRUG; VALPROIC ACID; VOLTAGE GATED POTASSIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL; CANNABINOID 1 RECEPTOR; CANNABIS; NABIXIMOLS; TETRAHYDROCANNABIVARIN 9;

ANTICONVULSANT ACTIVITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; EPILEPSY; HUMAN; NERVE CELL EXCITABILITY; NERVOUS SYSTEM INFLAMMATION; NEUROMODULATION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; DRUG COMBINATION; METABOLISM; TREATMENT OUTCOME;

ANIMALS; ANTICONVULSANTS; CANNABIDIOL; CANNABINOIDS; CANNABIS; DRONABINOL; DRUG COMBINATIONS; EPILEPSY; HUMANS; RECEPTOR, CANNABINOID, CB1; TREATMENT OUTCOME;

EID: 85009486504     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2016.11.016     Document Type: Review

References (57)

1. Rosenberg, E.C., Tsien, R.W., Whalley, B.J., Devinsky, O., Cannabinoids and epilepsy. Neurotherapeutics 12 (2015), 747–768.
2. Gaoni, Y., Mechoulam, R., Isolation, structure, and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86 (1964), 1646–1647.
3. Matsuda, L.A., Lolait, S.J., Brownstein, M.J., Young, A.C., Bonner, T.I., Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990), 561–564.
4. Wilson, R.I., Nicoll, R.A., Endocannabinoid signaling in the brain. Science 296 (2002), 678–682.
5. Pertwee, R.G., Cascio, M.G., Known pharmacological actions of delta-9-tetrahydrocannabinol and of four other chemical constituents of cannabis that activate cannabinoid receptors. Pertwee, RG, (eds.) Handbook of cannabis, 2014, Oxford University Press, Oxford, UK, 115.
6. Tsou, K., Brown, S., Sanudo-Pena, M., Mackie, K., Walker, J., Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83 (1998), 393–411.
7. Castillo, P.E., Younts, T.J., Chavez, A.E., Hashimotodani, Y., Endocannabinoid signaling and synaptic function. Neuron 76 (2012), 70–81.
8. Hua, T., Vemuri, K., Pu, M., Qu, L., Han, G.W., Wu, Y., et al. Crystal structure of the human cannabinoid receptor CB1. Cell 167 (2016), 750–762, e14.
9. Galiègue, S., Mary, S., Marchand, J., Dussossoy, D., Carrière, D., Carayon, P., et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232 (1995), 54–61.
10. Van Sickle, M.D., Duncan, M., Kingsley, P.J., Mouihate, A., Urbani, P., Mackie, K., et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310 (2005), 329–332.
11. Stempel, A.V., Stumpf, A., Zhang, H.Y., Ozdogan, T., Pannasch, U., Theis, A.K., et al. Cannabinoid type 2 receptors mediate a cell type-specific plasticity in the hippocampus. Neuron 90 (2016), 795–809.
12. Alger, B.E., Seizing an opportunity for the endocannabinoid system. Epilepsy Curr 14 (2014), 272–276.
13. Hill, A.J., Hill, T.D.M., Whalley, B.J., The development of cannabinoid based therapies for epilepsy. Onaivi, E.S., Darmani, N.A., Wagner, E., (eds.) Endocannabinoids: molecular, pharmacological, behavioral and clinical features, 2013, Bentham Science, 164–204.
14. Davis, J.P., Ramsey, H.H., Antiepileptic action of marijuana-active substances. Federation of American, Soc. Exp. Biol. 8 (1949), 284–285.
15. Friedman, D., Devinsky, O., Cannabinoids in the treatment of epilepsy. N. Engl. J. Med. 373 (2015), 1048–1058.
16. Cascio, M.G., Pertwee, R.G., Known pharmacological actions of nine nonpsychotropic phytocannabinoids. Pertwee, RG, (eds.) Handbook of cannabis, 2014, Oxford Unversity Press, Oxford, UK, 137.
17. Parents: THCA tincture works just as well as CBD for pediatric seizures. Here's how to make it, 2014 https://tokesignals.com/parents-thca-tincture-works-just-as-well-as-cbd-for-pediatric-seizures-heres-how-to-make-it/.
18. Hill, A.J., Weston, S.E., Jones, N.A., Smith, I., Bevan, S.A., Williamson, E.M., et al. Delta(9)-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats. Epilepsia 51 (2010), 1522–1532.
19. Pertwee, R.G., The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br. J. Pharmacol. 153 (2008), 199–215.
20. Wallace, M.J., Blair, R.E., Falenski, K.W., Martin, B.R., DeLorenzo, R.J., The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J. Pharmacol. Exp. Ther. 307 (2003), 129–137.
21. Wallace, M.J., Martin, B.R., DeLorenzo, R.J., Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Eur. J. Pharmacol. 452 (2002), 295–301.
22. Wallace, M.J., Wiley, J.L., Martin, B.R., DeLorenzo, R.J., Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur. J. Pharmacol. 428 (2001), 51–57.
23. Bisogno, T., Hanus, L., De Petrocellis, L., Tchilibon, S., Ponde, D.E., Brandi, I., et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol. 134 (2001), 845–852.
24. Ligresti, A., Moriello, A.S., Starowicz, K., Matias, I., Pisanti, S., De Petrocellis, L., et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J. Pharmacol. Exp. Ther. 318 (2006), 1375–1387.
25. Shu, H.F., Yu, S.X., Zhang, C.Q., Liu, S.Y., Wu, K.F., Zang, Z.L., et al. Expression of TRPV1 in cortical lesions from patients with tuberous sclerosis complex and focal cortical dysplasia type IIb. Brain Dev 35 (2013), 252–260.
26. Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 15 (2016), 270–278.
27. Ross, H.R., Napier, I., Connor, M., Inhibition of recombinant human T-type calcium channels by Delta9-tetrahydrocannabinol and cannabidiol. J. Biol. Chem. 283 (2008), 16124–16134.
28. Ibeas Bih, C., Chen, T., Nunn, A.V., Bazelot, M., Dallas, M., Whalley, B.J., Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics 12 (2015), 699–730.
29. Patel, R.R., Barbosa, C., Brustovetsky, T., Brustovetsky, N., Cummins, TR, Aberrant epilepsy-associated mutant Nav1.6 sodium channel activity can be targeted with cannabidiol. Brain 139 (2016), 2164–2181.
30. GW pharmaceuticals announces positive phase 3 pivotal study results for Epidiolex® (cannabidiol) in the treatment of Dravet syndrome. 2016 http://www.gwpharm.com/GW%20Pharmaceuticals%20Announces%20Positive%20Phase%203%20Pivotal%20Study%20Results%20for%20Epidiolex%20cannabidiol.aspx.
31. GW pharmaceuticals announces positive phase 3 pivotal trial results for Epidiolex®(cannabidiol) in the treatment of Lennox-Gastaut syndrome. 2016 http://www.gwpharm.com/GW%20Pharmaceuticals%20Announces%20Positive%20Phase%203%20Pivotal%20Trial%20Results%20for%20Epidiolex%20cannabidiol%20in%20the%20Treatment%20of%20Lennox-Gastaut%20Syndrome.aspx.
32. Ceulemans, B., Boel, M., Leyssens, K., Van Rossem, C., Neels, P., Jorens, P.G., et al. Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia 53 (2012), 1131–1139.
33. Sourbron, J., Schneider, H., Kecskes, A., Liu, Y., Buening, E.M., Lagae, L., et al. Serotonergic modulation as effective treatment for Dravet syndrome in a zebrafish mutant model. ACS Chem. Neurosci. 7 (2016), 588–598.
34. Devinsky, O., Cilio, M.R., Cross, H., Fernandez-Ruiz, J., French, J., Hill, C., et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 55 (2014), 791–802.
35. During, M.J., Spencer, D.D., Adenosine: a potential mediator of seizure arrest and postictal refractoriness. Ann. Neurol. 32 (1992), 618–624.
36. Rimmerman, N., Ben-Hail, D., Porat, Z., Juknat, A., Kozela, E., Daniels, M.P., et al. Direct modulation of the outer mitochondrial membrane channel, voltage-dependent anion channel 1 (VDAC1) by cannabidiol: a novel mechanism for cannabinoid-induced cell death. Cell Death Dis., 4, 2013, e949.
37. Vezzani, A., Aronica, E., Mazarati, A., Pittman, Q.J., Epilepsy and brain inflammation. Exp. Neurol. 244 (2013), 11–21.
38. Hill, A.J., Mercier, M.S., Hill, T.D., Glyn, S.E., Jones, N.A., Yamasaki, Y., et al. Cannabidivarin is anticonvulsant in mouse and rat. Br. J. Pharmacol. 167 (2012), 1629–1642.
39. Hill, T.D., Cascio, M.G., Romano, B., Duncan, M., Pertwee, R.G., Williams, C.M., et al. Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. Br. J. Pharmacol. 170 (2013), 679–692.
40. Huestis, M.A., Pharmacokinetics and metabolism of the plant cannabinoids. Pertwee, RG, (eds.) Δ 9- 461tetrahydrocannibinol, cannabidiol and cannabinol, 462, 2005, Springer, Cannabinoids. Berlin, 657–690 4.
41. Stott, C.G., White, L., Wright, S., Wilbraham, D., Guy, G.W., A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray. Eur. J. Clin. Pharmacol. 69 (2013), 1135–1147.
42. Huestis, M.A., Human cannabinoid pharmacokinetics. Chem. Biodivers. 4 (2007), 1770–1804.
43. Karschner, E.L., Schwilke, E.W., Lowe, R.H., Darwin, W.D., Herning, R.I., Cadet, J.L., et al. Implications of plasma Δ9-tetrahydrocannabinol, 11-Hydroxy-THC, and 11-nor-9-Carboxy-THC concentrations in chronic cannabis smokers. J. Anal. Toxicol. 33 (2009), 469–477.
44. Grotenhermen, F., Pharmacokinetics and pharmacodynamics of cannabinoids. Clin. Pharmacokinet. 42 (2003), 327–360.
45. Agurell, S., Carlsson, S., Lindgren, J.E., Ohlsson, A., Gillespie, H., Hollister, L., Interactions of delta 1-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography. Experientia 37 (1981), 1090–1092.
46. Deiana, S., Watanabe, A., Yamasaki, Y., Amada, N., Arthur, M., Fleming, S., et al. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive–compulsive behaviour. Psychopharmacology 219 (2012), 859–873.
47. Paudel, K.S., Hammell, D.C., Agu, R.U., Valiveti, S., Stinchcomb, A.L., Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers. Drug Dev. Ind. Pharm. 36 (2010), 1088–1097.
48. Ohlsson, A., Lindgren, J.E., Andersson, S., Agurell, S., Gillespie, H., Hollister, L.E., Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. Biomed. Environ. Mass Spectrom. 13 (1986), 77–83.
49. Zendulka, O., Dovrtelova, G., Noskova, K., Turjap, M., Sulcova, A., Hanus, L., et al. Cannabinoids and cytochrome P450 interactions. Curr. Drug Metab. 17 (2016), 206–226.
50. Stout, S.M., Cimino, N.M., Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab. Rev. 46 (2014), 86–95.
51. Barnes, M.P., Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert. Opin. Pharmacother. 7 (2006), 607–615.
52. Bland, T.M., Haining, R.L., Tracy, T.S., Callery, P.S., CYP2C-catalyzed delta (9)-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. Biochem. Pharmacol. 70 (2005), 1096–1103.
53. Yamaori, S., Okamoto, Y., Yamamoto, I., Watanabe, K., Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab. Dispos. 39 (2011), 2049–2056.
54. Jiang, R., Yamaori, S., Okamoto, Y., Yamamoto, I., Watanabe, K., Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metab. Pharmacokinet. 28 (2013), 332–338.
55. Consroe, P., Wolkin, A., Cannabidiol–antiepileptic drug comparisons and interactions in experimentally induced seizures in rats. J. Pharmacol. Exp. Ther. 201 (1977), 26–32.
56. Geffrey, A.L., Pollack, S.F., Bruno, P.L., Thiele, E.A., Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia 56 (2015), 1246–1251.
57. Gaston, T., Bebin, E., Szaflarski, J., Importance of monitoring clobazam and N-desmethylclobazam levels in treatment with cannabidiol (CBD) for epilepsy (S14.001). Neurology, 86(16), 2016 http://www.neurology.org/content/86/16_Supplement/S14.001.abstract.